Determination of protein binding of troglitazone stereoisomers by fluorometric titration

Biopharmaceutics and Drug Disposition

Volumn 18, Issue 3, 1997, Pages 241-257

  Izumi, T ^a   Hoshiyama, K ^a   Enomoto, S ^a   Sasahara, K ^a   Sugiyama, Y ^b  

^a DAIICHI SANKYO CO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

dansylsarcosine; fluorescence; protein binding; troglitazone

Indexed keywords

TROGLITAZONE;

ANIMAL TISSUE; ARTICLE; DRUG DETERMINATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; FLUOROMETRY; MOUSE; NONHUMAN; STEREOISOMERISM; THEORETICAL STUDY;

ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CHROMANS; DANSYL COMPOUNDS; FLUORESCENT DYES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MICE; PROTEIN BINDING; RATS; SARCOSINE; SERUM ALBUMIN; SPECIES SPECIFICITY; SPECTROMETRY, FLUORESCENCE; STEREOISOMERISM; THIAZOLES; THIAZOLIDINEDIONES; TITRIMETRY;

EID: 0030995272     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199704)18:3<241::AID-BDD17>3.0.CO;2-O     Document Type: Article

References (29)

1. M. Gibaldi and D. Perrier, Pharmacokinetics, Dekker, New York, 1982.
2. M. Rowland and T. N. Tozer, Clinical Pharmacokinetics: Concepts and Applications, Lea and Febiger, Philadelphia, PA, 1986.
3. F. Lapicque, N. Muller, E. Payan and N. Dubois, Protein binding and stereoselectivity of nonsteroidal anti-inflammatory drugs. Clin. Pharmacokinet., 25, 115-125 (1993).
4. T. Fujiwara, A. Yoshioka, T. Yoshioka, I. Ushiyama and H. Horikoshi, Characterization of new antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rat, Diabetes, 37, 1549-1558 (1988).
5. S. I. Suter, J. J. Nolan, P. Wallace, B. Gumbiner and J. M. Olefsky, Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabet. Care, 14, 1083-1086 (1992).
6. M. Shibukawa, T. Sawada, C. Nakao, T. Izumi and T. Nakagawa, High-performance frontal analysis for the study of protein binding of troglitazone (CS-045) in albumin solution and in human plasma, J. Chromatogr. A, 697, 337-347 (1995).
7. T. Izumi, S. Enomoto, K. Hoshiyama, K. Sasahara, M. Shibukawa, T. Nakagawa and Y. Sugiyama, Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, using an animal scale-up approach. J. Pharmacol. Exp. Ther., submitted.
8. G. Sudlow, D. J. Birkett and D. N. Wade, The characterization of two specific drug binding sites on human serum albumin, Mol. Pharmacol., 11, 824-832 (1975).
9. G. Sudlow, D. J. Birkett and D. N. Wade, Further characterization of specific drug binding sites on human serum albumin, Mol. Pharmacol., 12, 1052-1061 (1976).
10. S. Goya, A. Takadate, H. Fujino, M. Otagiri and K. Uekama, New fluorescence probes for drug-albumin interaction studies, Chem. Pharm. Bull., 30, 1363-1369 (1982).
11. T. Yoshikawa, Y. Sugiyama, Y. Sawada, T. Iga, M. Hanano, S. Kawasaki and M. Ynagida, Effect of late pregnancy on salicylate, diazepam, warfarin, and propranolol binding: use of fluorescent probes. Clin. Pharmacol. Ther., 36, 201-208 (1984).
12. C. F. Chingnell, Methods in Pharmacology, Vol.2, Appleton-Century-Crofts, New York, 1972.
13. Y. Sugiyama, T. Iga, S. Awazu and M. Hanano, Studies on ligand binding properties of Z-fraction from rat liver cytosol using 1-anilino-8-naphthalenesulfonate, Chem. Pharm. Bull., 26, 199-208 (1978).
14. Y. Sugiyama, Y. Suzuki, Y. Sawada, S. Kawasaki, T. Beppu, T. Iga and M. Hanano, Auramine O as a fluorescent probe for the binding of basic drugs to human α1-acid glycoprotein (α1-AG), Biochem. Pharmacol., 34, 821-829 (1985).
15. G. Sudlow, D. J. Birkett and D. N. Wade, Spectroscopic techniques in the study of protein binding: The use of 1-anilinno-8-naphthalenesulphonate as a fluorescent probe for the study of the binding of lophenoxic and lopanoic acids to human serum albumin, Mol. Pharmacol., 9, 649-657 (1973).
16. L. Klungosuuyr, Interaction of 8-anilino-1-naphthalenesulfonic acid with holo-and apophosphorylase b. Ligand effect, resolution, and reconstruction with pyridoxal 5′-phosphate, Biochemistry, 13, 1751-1757 (1974).
17. S. Nagase and H. Tanaka, Clinical Biochemical Data of Experimental Animal, Soft Science, Tokyo, 1986.
18. A. M. Guarino, J. B. Anderson, D. K. Starkweather and C. F. Chignell, Pharmacological studies of camptothecin (NSC-100880): Distribution, plasma protein binding, and biliary excretion, Cancer Chemother. Rep., 56, 95-101 (1973).
19. B. M. Mitruka and H. M. Rawnsley, Clinical Biochemical and Hematological Reference Values in Moral Experimental Animals, Masson, New York, 1977.
20. F. Bree, S. Urien, P. Nguyen, J. P. Tillement, A. Steiner and M. C. Vallat, Human serum albumin conformational changes as induced by renoxicam and modified by simultaneous diazepam binding, J. Pharm. Pharmacol., 45, 1050-1053 (1993).
21. S. Wanwimolruck, D. J. Birkett and P. M. Brooks, Structural requirements for drug binding to site II on human serum albumin, Mol. Pharmacol., 24, 458-463 (1983).
22. D. Mackay, H. R. Panjehshain and C. J. Bowmer, Analysis of the binding of fluorescent ligands to soluble proteins, Biochem. Pharmacol., 41, 2011-2018 (1991).
23. N. Muller, F. Lapicque, E. Drelon and P. Netter, Binding sites of fluorescent probes on human serum albumin, J. Pharm. Pharmacol., 46, 300-304 (1994).
24. M. R. Panjehshahin, C. J. Bowmer and M. S. Yates, Effect of valproic acid, its unsaturated metabolites and some structurally related fatty acids on the binding of warfarin and dansylsarcosine to human albumin, Biochem. Pharmacol., 41, 1227-1233 (1991).
25. S. Wanwimolruck, D. J. Birkett and P. M. Brooks, Structural requirements for drug binding to site II on human serum albumin, Mol. Pharmacol., 24, 458-463 (1983).
26. Y. Keita, W. Kratzer, W. Wörner and N. Rietbrock, Effect of fatty acids on the binding kinetics at the benzodiazepine binding site of glycated human serum albumin, Int. J. Clin. Pharmacol. Ther. Toxicol., 31, 337-341 (1993).
27. H. Takikawa, Y. Sugiyama, M. Hanano, M. Kurita, H. Yoshida and T. Sugimoto, A novel binding site for bile acids on human serum albumin, Biochim. Biophys. Acta, 926, 145-153 (1987).
28. T. Yoshikawa, Y. Sugiyama, Y. Sawada, T. Iga and M. Hanano, Hepatic extraction of endogenous inhibitors of drug binding to serum protein in the pregnant rat, Biochem. Pharmacol., 34, 2733-2739 (1985).
29. T. Izumi, S. Enomoto, K. Hoshiyama, K. Sasahara and Y. Sugiyama, Stereoselectivity of troglitazone pharmacokinetics, an antidiabetic agent, in the KK mouse. Biopharm. Drug Disposit., submitted.